Contineum Therapeutics, Inc.
CTNM
$4.95
$0.337.14%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -42.26M | -35.46M | -31.45M | 19.13M | 22.72M |
| Total Depreciation and Amortization | 258.00K | 220.00K | 201.00K | 183.00K | 195.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -26.00K | 0.00 |
| Total Other Non-Cash Items | 3.82M | 2.30M | 295.00K | -2.93M | -2.54M |
| Change in Net Operating Assets | 5.33M | -406.00K | -1.61M | 265.00K | -1.02M |
| Cash from Operations | -32.85M | -33.35M | -32.56M | 16.62M | 19.35M |
| Capital Expenditure | -514.00K | -657.00K | -597.00K | -509.00K | -414.00K |
| Sale of Property, Plant, and Equipment | 20.00K | 20.00K | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -69.25M | -50.68M | -60.04M | -65.68M | -65.15M |
| Cash from Investing | -69.74M | -51.32M | -60.63M | -66.19M | -65.57M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 0.00 | 0.00 | -3.13M | -3.75M |
| Issuance of Common Stock | 109.00M | 108.41M | 108.48M | 273.00K | 159.00K |
| Repurchase of Common Stock | -- | -28.00K | -28.00K | -28.00K | -28.00K |
| Issuance of Preferred Stock | -- | 0.00 | 10.24M | 60.14M | 60.14M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -343.00K | -343.00K | -483.00K | -343.00K |
| Cash from Financing | 109.00M | 108.04M | 118.35M | 56.78M | 56.18M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 6.42M | 23.37M | 25.16M | 7.20M | 9.96M |